Axol Bioscience acquires ophthalmology business from Newcells Biotech
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The partnership initially will focus on cardiovascular and kidney diseases
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
Subscribe To Our Newsletter & Stay Updated